Medulloblastoma: tumorigenesis, current clinical paradigm, and efforts to improve risk stratification

  title={Medulloblastoma: tumorigenesis, current clinical paradigm, and efforts to improve risk stratification},
  author={William R. Polkinghorn and Nancy J. Tarbell},
  journal={Nature Clinical Practice Oncology},
Medulloblastoma is the most common brain malignancy in children and tremendous advances have recently been made in understanding the pathogenesis of this tumor. The Hedgehog and Wingless signaling pathways are implicated in medulloblastoma development, and both pathways were discovered as a result of analyses of genetic syndromes associated with the tumor. Over the past 80 years, considerable progress has been made in the treatment of what was once a fatal disease. The first survival reports… 

Medulloblastoma: From Molecular Pathology to Therapy

Better understanding of the growth control mechanisms involved in the development and progression of medulloblastoma will allow a better classification, leading to the improvement of the existing therapies, as well as to the development of new therapeutic approaches.

Where are we with Targeted Therapies for Medulloblastoma

Five year overall survival rates with high risk medulloblastoma are up to 65% and can be greater than 80% in patients in those with average risk disease using current standard-of-care multimodal therapy that includes surgery, craniospinal radiation and chemotherapy.

Clinical , Histopathologic , Radiographic and Molecular Classification of Medulloblastoma

The utility and limitations of the clinical, histopathological, radiographic, and molecular characteristics of medulloblastoma that are used to classify patients and guide therapeutic decisions are summarized.

Clinical, Histopathologic, Radiographic and Molecular Classification of

The clinical, histopathologic, radiographic, and molecular characteristics of both pediatric and adult medulloblastoma are summarized to facilitate modification of therapy with reduced toxicity in some cases, while improving clinical outcome with targeted therapies in others.

Pediatric medulloblastoma in the molecular era: what are the surgical implications?

Using the four main molecular MB subgroups, a restratification into clinicogenomic risk categories quantified an unacceptable survival for the high-risk group, urging researchers to focus their efforts towards acquiring a greater biological understanding of these children.

Antiangiogenic Strategies in Medulloblastoma: Reality or Mystery

The state-of-the-art concerning antiangiogenic targets for medulloblastoma treatment is reviewed, and the complexity of the vascular system that intrinsically limits the efficacy of current strategies is discussed.

Molecular biology of medulloblastoma: bridging the gap between research and practice

A novel four-antibody approach to subgroup medulloblastoma using immunohistochemistry on archival specimens as proposed by Northcott et al appears extremely promising as it can be applied in any basic neuropathology laboratory across the globe.

The rationale for targeted therapies in medulloblastoma.

Current preclinical and clinical data, as well as data from clinical trials of targeted therapies that are either ongoing or in development for medulloblastoma are discussed.

Accumulation of genomic aberrations during clinical progression of medulloblastoma

It is suggested that early recurrence in medulloblastoma mainly occurs in tumors with a highly malignant genotype and phenotype per se, whereas late recurrence is often dependent on tumor evolution toward a more malignant biology.



Anaplasia and Grading in Medulloblastomas

It is believed anaplastic change represents a type of malignant progression common to many medulloblastoma subtypes and to other CNS embryonal lesions as well, and correlation of these histological changes with the accumulation of genetic events suggests a model for the histological and molecular progression of medullOBlastoma.

Atypical teratoid/rhabdoid tumor: the controversy behind radiation therapy

A review of the literature reveals an association between initial radiation therapy and the ability to achieve a prolonged survival and underscores the importance or enrolling patients in multi-institutional prospective studies to further investigate the value of radiation to treat this pediatric neoplasm.

Molecular Insight into Medulloblastoma and Central Nervous System Primitive Neuroectodermal Tumor Biology from Hereditary Syndromes: A Review

The published literature describing hereditary syndromes that have been associated with an increased incidence of medulloblastoma and/or central nervous system primitive neuroectodermal tumor is reviewed.

Current treatment approaches to early childhood medulloblastoma

Future studies will clarify the prognostic relevance of desmoplasia, postoperative residual tumor and biological markers to improve stratification criteria by risk-adapted treatment recommendations.

Medulloblastoma: Present Concepts of Stratification into Risk Groups

Staging studies have been used to stratify children with medulloblastoma into risk groups, but age at diagnosis and amount of residual disease after surgery or extent of resection have also been commonly incorporated into stratification schemata.

Clinical and molecular stratification of disease risk in medulloblastoma

The hypothesis that a combination of clinical and molecular factors may afford a more reliable means of assigning disease risk in patients with medulloblastoma is supported, thereby providing a more accurate basis for targeting therapy in children with this disease.

Medulloblastomas With Systemic Metastases: Evaluation of Tumor Histopathology and Clinical Behavior in 23 Patients

Metastasis of medulloblastomas outside the CNS can occur after long periods of clinical remission and is associated with anaplasia in some cases, consistent with tumor progression.

Histopathologic grading of medulloblastomas

The authors evaluated the clinical effects of increasing anaplasia and nodularity in a large group of children with medulloblastomas, hypothesizing that increasing nodularity would predict better clinical outcomes and that increasing anaPlasia would presage less favorable results.

Staging, scoring and grading of medulloblastoma

It is concluded that this new staging, scoring and grading system is a simple and recommendable prognostic system for all patients treated surgically for medulloblastoma.

The treatment and prognosis of medulloblastoma in children. A study of 82 verified cases.

The survival rate is greater for patients in whom a "complete" surgical excision of the tumor was performed, compared with lesser procedures, and in some cases with brain-stem involvement radiotherapy can cure or control locally advanced disease for an appreciable time.